Biotronik/Aachen Lekton Vita DES Slated For Q4 2004 European Launch
This article was originally published in The Gray Sheet
Executive SummaryAachen Resonance will begin a randomized trial of its Tretinoin compound on Biotronik's Lekton Motion stent system early next year under a Nov. 19 pact giving Biotronik commercialization rights
You may also be interested in...
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.